BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23718670)

  • 1. [Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].
    Poprach A; Lakomý R; Selingerová I; Dolečková B; Bílek O; Slabý O; Héžová R; Fabian P; Staník M; Pavlík T; Bortlíček Z; Mlčochová H; Tkáč D; Vyzula R; Kiss I; Kocák I; Kocáková I; Svoboda M
    Klin Onkol; 2013; 26(2):114-23. PubMed ID: 23718670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of extensive necrosis in renal cell carcinoma.
    Collins J; Epstein JI
    Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
    de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
    Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.
    Tornberg SV; Visapää H; Kilpeläinen TP; Taari K; Järvinen R; Erkkilä K; Nisen H; Järvinen P
    Scand J Urol; 2018; 52(5-6):419-426. PubMed ID: 30663485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 14. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.
    Amin MB; Corless CL; Renshaw AA; Tickoo SK; Kubus J; Schultz DS
    Am J Surg Pathol; 1997 Jun; 21(6):621-35. PubMed ID: 9199639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
    Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
    J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
    Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.